Literature DB >> 7171229

Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.

J Salk, P Stoeckel, A L van Wezel, K Lapinleimu, G van Steenis.   

Abstract

The immunologic response to inactivated poliovirus vaccine following one and two doses has been studied in infants in developing and developed countries using vaccine prepared at the Rijks Instituut voor de Volksgezondheit, The Netherlands. Virus was grown in microcarrier cultures of monkey kidney cells, purified, concentrated, and inactivated with formalin. The vaccines used contained different quantities of D-antigen units for each of the three types. The data reveal that both antibody and immunologic memory (booster-type responsiveness) were induced in virtually all individuals following a single dose of a sufficient quantity of antigen. Immunologic memory was readily revealed by the booster-type response following a second dose given six months after the first. The degree of booster-type response to a second dose is linked primarily to the quantity of antigen used for primary immunization, and secondarily to the quantity of antigen used for the booster dose. The data base is presented for formulating the antigen content of an inactivated poliovirus vaccine that can be relied upon to be protective after the first dose when given alone or when incorporated with combinations of other antigens (diphtheria-per tussis-tetanus) that may require two or more doses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7171229

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  5 in total

1.  Poliomyelitis in North America: the disease is not dead yet.

Authors:  E G Morrison; J A Embil
Journal:  CMAJ       Date:  1987-12-15       Impact factor: 8.262

Review 2.  Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability.

Authors:  Carl T D'Angio
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Authors:  Xavier Sáez-Llorens; Ralf Clemens; Geert Leroux-Roels; José Jimeno; Sue Ann Costa Clemens; William C Weldon; M Steven Oberste; Natanael Molina; Ananda S Bandyopadhyay
Journal:  Lancet Infect Dis       Date:  2015-12-21       Impact factor: 71.421

Review 4.  Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Authors:  Nicholas C Grassly
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226

5.  Mass immunization with inactivated polio vaccine in conflict zones--Experience from Borno and Yobe States, North-Eastern Nigeria.

Authors:  Faisal M Shuaibu; Gerida Birukila; Samuel Usman; Ado Mohammed; Michael Galway; Melissa Corkum; Eunice Damisa; Pascal Mkanda; Frank Mahoney; Gatei Wa Nganda; John Vertefeuille; Anna Chavez; Sule Meleh; Richard Banda; Almai Some; Hyelni Mshelia; Al-Umra Umar; Ogu Enemaku; Andrew Etsano
Journal:  J Public Health Policy       Date:  2015-11-05       Impact factor: 2.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.